Heart failure & cardiomyopathiesCohort study

Cardiac allograft vasculopathy and secondary outcomes at 1-year in heart transplantation from circulatory death donors

Am Heart JPublished

  • registry analysis using unadjusted and adjusted logistic regression with propensity-score matched cohorts
  • UNOS registry
  • propensity-score matched within the same heart-transplantation (HT) centers

Authors' conclusion

One-year CAV and other key secondary clinical outcomes were similar DBD and DCD-HT recipients, irrespective of DPP or NRP procurement method. Intermediate and long-term CAV risk in DCD-HT needs to be further clarified.

Study context

Population
Adult heart transplants performed between January 2020 and June 2024 with follow-up through June 2025, with 1-year survivaleligible transplants with 1-year survival · DBD 11,393 · DCD 1,237
Participants
12,630 participants
Exposure
One-year cardiac allograft vasculopathy (CAV) was compared between DBD and DCD recipients
  • DBDn = 11,393
  • DCDn = 1,237

Main finding

1-year CAV · 1 year

Adjusted odds ratio

0.99

95% CI 0.77–1.28

P = 0.94

By group

DCD vs DBD
adjusted OR 0.99 (95% CI 0.77–1.28); P = 0.94

As reported in the abstract

Observational data: associations, not effects.

Secondary outcomes

OutcomeDBDDCDOR (95% CI)P value
CAV in propensity-matched pairs from the same centers · direction of ratio not stated in abstract6.51%5.61%0.85 (0.60–1.21)P = 0.37
  • CAV in propensity-matched pairs from the same centers: 1,106 propensity-matched pairs

Secondary outcomes (chronic dialysis, hospitalization for infection or rejection, impaired functional status)

comparable

CAV risk by DCD procurement method (DPP and NRP)

no significant differences in CAV risk

Original publication

Cardiac allograft vasculopathy and secondary outcomes at 1-year in heart transplantation from circulatory death donors. Am Heart J. Published 14 August 2026. doi:10.1016/j.ahj.2026.107574

Summarised from the published abstract; every number is checked against it